Bialik V, Bialik G M, Blazer S, Sujov P, Wiener F, Berant M
Pediatric Orthopedics Unit, Rambam Medical Center, Faculty of Medicine,Technion-Israel Institute of Technology, Haifa, Israel.
Pediatrics. 1999 Jan;103(1):93-9. doi: 10.1542/peds.103.1.93.
The controversy over the incidence of developmental dysplasia of the hip (DDH) stems mainly from an ambiguity of criteria for defining a genuinely pathologic neonatal hip. In this study, we evaluate an algorithm we devised for the treatment of DDH, for its ability to identify those neonatal hips which, if left untreated, would develop any kind of dysplasia and, therefore, are to be included in the determination of DDH incidence.
Clinical and ultrasonographic examinations for DDH were performed on 18 060 consecutive neonatal hips at 1 to 3 days of life. Newborns with skeletal deformities, neurologic/muscular disorders, and neural tube defects were excluded. Hips that featured any type of sonographic pathology were reexamined at 2 or 6 weeks, depending on the severity of the findings. Only hips in which the initial pathology was not improved or had deteriorated were treated; all others were examined periodically until the age of 12 months.
Sonographic screening of 18 060 hips detected 1001 instances of deviation from normal, indicating a sonographic DDH incidence of 55.1 per 1000. However, only 90 hips remained abnormal and required treatment, indicating a true DDH incidence of 5 per 1000 hips. All the others evolved into normal hips, and no additional instances of DDH were found on follow-up throughout the 12 months.
The implementation of our protocol enables us to distinguish two categories of neonatal hip pathology: one that eventually develops into a normal hip (essentially sonographic DDH); and another that will deteriorate into a hip with some kind of dysplasia, including full dislocation (true DDH). This approach seems to allow for a better-founded definition of DDH, for an appropriate determination of its incidence, for decision-making regarding treatment, and for assessment of the cost-effectiveness of screening programs for the early detection of DDH.
关于发育性髋关节发育不良(DDH)发病率的争议主要源于定义真正病理性新生儿髋关节的标准不明确。在本研究中,我们评估了我们设计的一种用于治疗DDH的算法,看其能否识别那些如果不治疗就会发展为任何类型发育不良的新生儿髋关节,从而将其纳入DDH发病率的确定中。
对18060例出生1至3天的连续新生儿髋关节进行DDH的临床和超声检查。排除有骨骼畸形、神经/肌肉疾病和神经管缺陷的新生儿。根据检查结果的严重程度,对有任何类型超声病理特征的髋关节在2周或6周时进行复查。只有初始病理没有改善或恶化的髋关节才进行治疗;其他所有髋关节定期检查直至12个月龄。
对18060个髋关节进行超声筛查发现1001例偏离正常情况,表明超声诊断的DDH发病率为每1000例中有55.1例。然而,只有90个髋关节仍异常并需要治疗,表明真正的DDH发病率为每1000个髋关节中有5例。其他所有髋关节都发育为正常髋关节,在整个12个月的随访中未发现额外的DDH病例。
我们方案的实施使我们能够区分两类新生儿髋关节病理情况:一类最终发育为正常髋关节(本质上是超声诊断的DDH);另一类会恶化为有某种发育不良的髋关节,包括完全脱位(真正的DDH)。这种方法似乎能为DDH提供更有依据的定义,能更恰当地确定其发病率,有助于治疗决策,也有助于评估早期检测DDH的筛查项目的成本效益。